Business Context and Reporting Period
This Form 8-K is a current report filed by TopSpin Medical, Inc. (not My Size, Inc.) on September 25, 2007. The filing details significant corporate governance changes, including the resignation of the Chief Executive Officer (CEO), the appointment of a new CEO, and amendments to executive compensation and stock option plans.
Key Financial Metrics and Compensation
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or debt levels. Instead, it discloses specific compensation arrangements and equity grants:
- Outgoing CEO (Erez Golan): Received a $10,000 payment pursuant to his employment agreement and a $20,000 bonus. He entered a consulting agreement with a base fee of $7,750 per month (approx. 5 days/month) plus $1,500 per additional day if he works 15+ days in a quarter.
- New CEO (Yaron Tal): Granted a monthly gross salary of 65,000 NIS (Israeli Shekels), adjusted quarterly for inflation. He is eligible for performance bonuses up to 7.5 times the monthly salary for the initial period and 6 times thereafter, with an automatic bonus of 4.5 times the monthly salary for the initial period.
- Other Executives: CFO Eyal Kolka received a $50,000 cash bonus. Both Kolka and COO Yoav Venkert received salary increases to 47,300 NIS per month.
- Equity Grants: The Board approved a grant of options for 10,000,000 shares to the new CEO at a weighted-average exercise price of $0.13545. The total shares authorized under the 2003 Israeli Stock Option Plan were increased by 15,000,000 to a total of 37,000,000 shares.
Material Changes Versus Prior Period
The primary material change is the leadership transition effective October 1, 2007:
- Departure: Erez Golan resigned as President and CEO. He remains a director and beneficial owner of over 5% of the company's common stock.
- Appointment: Yaron Tal was appointed President and CEO. He previously served as CEO of Galil Medical Ltd. (2003–2007) and holds an Israeli C.P.A. license.
- Compensation Structure: Significant restructuring of executive pay, including new employment agreements, accelerated vesting for the outgoing CEO's options, and a substantial increase in the authorized share pool for stock options.
Guidance, Outlook, and Risks
The filing contains no financial guidance, revenue outlook, or management commentary regarding future business performance. Key contingencies and risks identified include:
- Intellectual Property: Both the outgoing and incoming executive agreements stipulate that the subsidiary owns all rights to patents and inventions arising from their services.
- Termination Clauses: The new CEO's employment agreement includes specific notice periods (4 to 6 months) for termination without cause, though immediate termination is permitted for cause.
- Change in Control: All unvested options granted to the new CEO will vest immediately upon a change in control or sale of substantially all assets.
Important Facts for Investor Verification
- Verify the total cash outflow for executive compensation ($30,000 to Golan, $50,000 to Kolka, plus ongoing salary obligations) against the company's current liquidity position.
- Confirm the dilution impact of the 10,000,000 new options granted to the new CEO and the 15,000,000 increase in the authorized option pool.
- Review the full text of the Consulting Agreement (Exhibit 10.29) to understand the scope of services and potential conflicts of interest given Golan's continued 5% ownership.
- Assess the experience of the new CEO, Yaron Tal, specifically his background at Galil Medical Ltd., to gauge strategic continuity.